Halozyme Therapeutics vs Bio-Techne
Halozyme Therapeutics (HALO), health care, and Bio-Techne (TECH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Bio-Techne is worth $11.4B on the stock market and Halozyme Therapeutics $10.9B: Bio-Techne is valued at 4% more. Halozyme Therapeutics trades at 24.0 times earnings and Bio-Techne at 66.6; operating margins in their latest fiscal years were 33.6% and 20.7%. Over the past year Halozyme Therapeutics's share price has moved +37.7% and Bio-Techne's +25.2%.
Key facts
- Halozyme Therapeutics market value
- $10.9B
- Bio-Techne market value
- $11.4B
- Halozyme Therapeutics P/E
- 24.0
- Bio-Techne P/E
- 66.6
- Halozyme Therapeutics revenue
- $1.4BFY to 2025-12-31
- Bio-Techne revenue
- $1.2BFY to 2026-06-30
- Superinvestors holding both
- 0
Market values as of .
| Measure | Halozyme Therapeutics | Bio-Techne |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-06-30 |
| Size | ||
| Market cap | $10.9Blower | $11.4Bhigher |
| Revenue | $1.4Bhigher | $1.2Blower |
| Earnings | $316.9Mhigher | $181.9Mlower |
| Employees | 423lower | 3,000higher |
| Total assets | $2.5Blower | $2.6Bhigher |
| Valuation | ||
| P/E | 24.0lower | 66.6higher |
| P/S | 7.8lower | 9.4higher |
| P/B | — | 5.3 |
| Dividend yield | 0.00%lower | 0.33%higher |
| Profitability | ||
| Operating margin | 33.6%higher | 20.7%lower |
| Balance sheet | ||
| Net assets | $48.8Mlower | $2.1Bhigher |
| Total liabilities | $2.5Bhigher | $478.5Mlower |
| Total debt | $2.1Bhigher | $200Mlower |
| Cash on hand | $133.8Mlower | $264.7Mhigher |
| Price change | ||
| Today | -0.55%lower | -0.22%higher |
| 1 year | +37.7%higher | +25.2%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Halozyme Therapeutics only (5)
Bio-Techne only (7)
- Sequoia Fund team3.9%
- Wallace Weitz1.3%
- Lee Ainslie1.0%
- Mairs & Power team0.8%
- Henry Ellenbogen0.3%
- Paul Tudor Jones0.3%
- Larry Robbins0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns HALO · Who owns TECH
More on Halozyme Therapeutics
Further comparisons
Halozyme Therapeutics against its closest peers
Bio-Techne against its closest peers
Learn
Questions and answers
Which is bigger, Halozyme Therapeutics or Bio-Techne?
By market value, Bio-Techne is the larger: $11.4B against $10.9B for Halozyme Therapeutics. By revenue in its latest fiscal year, Halozyme Therapeutics is the larger: $1.4B against $1.2B for Bio-Techne.
Which has the higher P/E ratio?
Bio-Techne: 66.6, against 24.0 for Halozyme Therapeutics. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Halozyme Therapeutics: 33.6%, against 20.7% for Bio-Techne. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Bio-Techne: 0.33%, against 0.00% for Halozyme Therapeutics. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Halozyme Therapeutics: $2.1B, against $200M for Bio-Techne. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Halozyme Therapeutics and Bio-Techne?
None of the tracked superinvestors holds both in their latest 13F filing. 5 hold Halozyme Therapeutics and 7 hold Bio-Techne.
Cite this page
Funkfolio, “Halozyme Therapeutics vs Bio-Techne”, data as of 17 November 2026. https://funkfolio.com/compare/halo-vs-tech
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.